Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. 2004

Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
Department of Internal Medicine I, Section for Pulmonary Diseases, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany. hleuchte@helios.med.uni-muenchen.de

OBJECTIVE Different vasodilators and different routes of application are used for the treatment of primary pulmonary hypertension (PPH). Recently, sildenafil, a phosphodiesterase-V inhibitor, has been shown to have beneficial hemodynamic effects in PPH. However, the hemodynamic effects of sildenafil have not been characterized and compared to other vasodilators such as inhaled nitric oxide (iNO) or iloprost in PPH in the same group of patients. METHODS We investigated prospectively 10 consecutive patients with PPH using iNO, iloprost aerosol, and oral sildenafil to test acute hemodynamic response during right-heart catheterization. RESULTS iNO, iloprost aerosol, and sildenafil caused a significant fall of mean pulmonary artery pressure and pulmonary vascular resistance (PVR) [p < 0.05]. Correspondingly, cardiac output and mixed venous saturation increased slightly in all groups. Systemic arterial pressure and vascular resistance were mainly unaltered. Using a PVR reduction of > or =20% to define a significant response, 7 of 10 patients were responders to iloprost aerosol, whereas 4 of 10 patients responded to iNO and oral sildenafil. Improvement of oxygenation as indicated by an increase of arterial oxygen tension was observed with iloprost aerosol (p < 0.01). CONCLUSIONS All of the three substances, iNO, iloprost aerosol, and oral sildenafil, significantly improved pulmonary hemodynamics in patients with PPH. The most prominent hemodynamic effects and improvement of oxygenation were observed with iloprost aerosol.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
October 2007, Respiratory medicine,
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
May 1998, Lancet (London, England),
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
September 2002, The American journal of cardiology,
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
August 1998, Lancet (London, England),
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
June 2005, Current opinion in pharmacology,
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
January 2005, Przeglad lekarski,
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
January 2000, Journal of the American College of Cardiology,
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
February 2015, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
September 2001, Circulation,
Hanno H Leuchte, and Martin Schwaiblmair, and Rainer A Baumgartner, and Claus F Neurohr, and Tilman Kolbe, and Jürgen Behr
May 1997, The Journal of surgical research,
Copied contents to your clipboard!